Cancer is a major cause of death in patients with kidney transplants. The incidence of cancer after transplant is 3- to 100-fold higher than that in the general population, and cancer has been shown to be one of the most feared outcomes in patients with kidney transplants (1, 2). However, data on cancer screening and treatment efficacies of novel cancer therapies in patients with kidney transplants are lacking, as these patients have been typically excluded from clinical studies.
Immune checkpoint inhibitors (ICIs) have revolutionized cancer treatment and become standard therapy for many cancers. They work by
A llogeneic stem cell transplant (SCT) is used to cure several hematological disorders. The incidence of both acute kidney injury and chronic kidney disease (CKD) post-SCT remains high. A rare cause of CKD post-allogeneic SCT is development of glomerular disease, which by many is considered to be a manifestation of chronic graft-versus-host disease (GVHD) affecting the kidney (1). Based on mouse models, it has been proposed that GVHD could be a direct T cell-mediated injury or that the chronic systemic inflammatory state of GVHD leads to autoimmune induction and glomerulopathy (2). The incidence of nephrotic syndrome